Pamidronaatdinatrium Hospira (Pamidronate Disodium)

Pamidronate Disodium, the active ingredient in Pamidronaatdinatrium Hospira, is a bisphosphonate presented as a sterile powder for intravenous infusion use. It is employed in the management of bone resorption disorders, particularly in patients with malignancy‑related hypercalcaemia and metastatic bone disease.

GNH USA supplies Pamidronaatdinatrium Hospira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Pamidronate Disodium is used in several bone‑related clinical pathways, especially those involving abnormal calcium metabolism. - Hypercalcaemia of malignancy: reduces elevated serum calcium levels. - Osteolytic bone metastases: helps limit the progression of skeletal lesions. - Paget’s disease of bone: decreases abnormal bone turnover. - Osteoporosis associated with long‑term glucocorticoid therapy: lowers fracture risk. - Primary hyperparathyroidism pre‑operative preparation: assists in normalising calcium before surgery.

Adverse reactions to pamidronate are reported across a spectrum of frequency and severity.

Common Side Effects: - Acute infusion‑related flu-like symptoms (fever, chills, myalgia). - Nausea or vomiting. - Transient elevation of serum creatinine. - Musculoskeletal pain, especially in the back or limbs. - Headache.

Serious or Rare Side Effects: - Acute renal insufficiency or failure. - Severe hypocalcaemia. - Osteonecrosis of the jaw (ONJ). - Atypical femoral fractures. - Anaphylactic or severe hypersensitivity reactions.

When using Pamidronate Disodium, clinicians should observe several safety measures. - Renal function monitoring: assess baseline creatinine and adjust dosing if impairment exists. - Calcium and vitamin D status: correct deficiencies before infusion to reduce hypocalcaemia risk. - Concomitant nephrotoxic drugs: avoid or use with caution. - Dental health: perform dental examination and complete invasive procedures before therapy. - Pregnancy and lactation: contraindicated unless clearly needed; discuss risks with a specialist. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Pamidramate may interact with several medicines that influence renal function or calcium balance.

Major Interactions (Avoid): - Aminoglycoside antibiotics (e.g., gentamicin): increase risk of nephrotoxicity. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potentiate renal impairment. - Loop diuretics (furosemide): may exacerbate hypocalcaemia.

Moderate Interactions (Monitor Closely): - Calcium supplements or antacids containing calcium: can reduce pamidronate efficacy. - Vitamin D analogues: require careful monitoring of serum calcium. - Corticosteroids: may increase risk of osteonecrosis when combined with bisphosphonates.